ASCO GU 2021: Tivozanib in Patients with Advanced Renal Cell Carcinoma (aRCC) who have Progressed After Prior Treatment with Axitinib: Results from TIVO-3
Tag: Tivozanib
ASCO GI 2021: DEDUCTIVE: a Study of Tivozanib in Combination with Durvalumab in Subjects with Untreated Advanced Hepatocellular Carcinoma; Phase Ib results
ASCO GI 2021: DEDUCTIVE: a Study of Tivozanib in Combination with Durvalumab in Subjects with Untreated Advanced Hepatocellular Carcinoma; Phase Ib results
TiNivo: Safety and Efficacy of Tivozanib-Nivolumab Combination Therapy in Patients With Metastatic Renal Cell Carcinoma
Authors: L. Albiges, P. Barthélémy, M. Gross-Goupil, S. Negrier, M. N. Needle, B. Escudier. Click here for link to article.
Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma
Authors: Sumanta K. Pal, Bernard J. Escudier, Michael B. Atkins, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael N. Needle, Daniel Powers, David F. McDermott, Brian I. Rini. Click here for link to article.
ASCO 2020: TIVO-3: Final OS analysis of a randomized, controlled, multi-center, open-label phase 3 study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC)
ASCO 2020: TIVO-3: Final OS analysis of a randomized, controlled, multi-center, open-label phase 3 study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC)
Real-World Results from One Year of Therapy with Tivozanib
Authors: Michael Staehler, Annabel K. Spek, Severin Rodler, Melanie Schott, Jozefina Casuscelli, Lena Mittelmeier, Marcus Schlemmer. Click here for link to article.
KCS 2019: TIVO-3: A Phase 3 Study to Compare Tivozanib to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma (RCC): Overall Survival 2-Year Update
KCS 2019: TIVO-3: A Phase 3 Study to Compare Tivozanib to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma (RCC): Overall Survival 2-Year Update
ESMO 2019: TiNivo: Tivozanib Combined With Nivolumab Results in Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Carcinoma (mRCC) – Final Results
ESMO 2019: TiNivo: Tivozanib Combined With Nivolumab Results in Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Carcinoma (mRCC) – Final Results
ASCO 2019: TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)
ASCO 2019: TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)
ASCO GU 2019: TIVO-3: A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma (RCC)
ASCO GU 2019: TIVO-3: A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma (RCC)